索拉非尼联合介入治疗晚期肝癌进展

Research Progress on Sorafenib Combined with Intervention in the Treatment for Advanced Hepatocellular Carcinoma

索拉非尼是一种用于晚期肝癌的小分子多靶点激酶抑制剂,索拉非尼治疗原发性肝癌的Ⅲ期临床研究试验结果表明,其能显著提高患者生存率。介入治疗,如射频消融、肝动脉化疗栓塞作为目前治疗不可手术切除晚期肝癌的重要手段,其应用于临床已取得满意的效果,这在一定程度上为晚期肝癌非手术治疗提供了更多的选择。索拉非尼联合介入治疗晚期肝癌提高患者生存期已有文献报道且疗效肯定。

Sorafenib is a multi-targeted small molecule kinase inhibitors for advanced liver cancer. Clinical trails of sorafenib treatment for phase Ⅲ primary liver cancer showed that it can improve the survival rate of the patients significantly. Interventional treatment,such as radiofrequency ablation and transarterial chemoembolization,has achieved satisfactory clinical results as an important means to treat unresectable advanced hepatocellular carcinoma,which has achieved,which has provided more options for non-operative treatment for advanced liver cancer. The positive effect of sorafenib combined with interventional therapy on advanced liver cancer has been reported in the literatures. Here is to make a review of the biological therapy,interventional therapy for advanced liver cancer,in order to help for clinicians in selecting proper treatment for advanced liver cancer.